11-70469624-A-G
Position:
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBS1_SupportingBS2
The NM_012309.5(SHANK2):c.*3245T>C variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0123 in 152,646 control chromosomes in the GnomAD database, including 24 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.012 ( 24 hom., cov: 33)
Exomes 𝑓: 0.015 ( 0 hom. )
Consequence
SHANK2
NM_012309.5 3_prime_UTR
NM_012309.5 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 1.03
Genes affected
SHANK2 (HGNC:14295): (SH3 and multiple ankyrin repeat domains 2) This gene encodes a protein that is a member of the Shank family of synaptic proteins that may function as molecular scaffolds in the postsynaptic density of excitatory synapses. Shank proteins contain multiple domains for protein-protein interaction, including ankyrin repeats, and an SH3 domain. This particular family member contains a PDZ domain, a consensus sequence for cortactin SH3 domain-binding peptides and a sterile alpha motif. The alternative splicing demonstrated in Shank genes has been suggested as a mechanism for regulating the molecular structure of Shank and the spectrum of Shank-interacting proteins in the postsynaptic densities of the adult and developing brain. Alterations in the encoded protein may be associated with susceptibility to autism spectrum disorder. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -9 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.74).
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.0123 (1866/152308) while in subpopulation NFE AF= 0.0167 (1135/68032). AF 95% confidence interval is 0.0159. There are 24 homozygotes in gnomad4. There are 906 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High AC in GnomAd4 at 1866 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SHANK2 | NM_012309.5 | c.*3245T>C | 3_prime_UTR_variant | 26/26 | ENST00000601538.6 | NP_036441.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SHANK2 | ENST00000601538 | c.*3245T>C | 3_prime_UTR_variant | 26/26 | 5 | NM_012309.5 | ENSP00000469689.2 |
Frequencies
GnomAD3 genomes AF: 0.0123 AC: 1866AN: 152190Hom.: 24 Cov.: 33
GnomAD3 genomes
AF:
AC:
1866
AN:
152190
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0148 AC: 5AN: 338Hom.: 0 Cov.: 0 AF XY: 0.0101 AC XY: 2AN XY: 198
GnomAD4 exome
AF:
AC:
5
AN:
338
Hom.:
Cov.:
0
AF XY:
AC XY:
2
AN XY:
198
Gnomad4 FIN exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0123 AC: 1866AN: 152308Hom.: 24 Cov.: 33 AF XY: 0.0122 AC XY: 906AN XY: 74484
GnomAD4 genome
AF:
AC:
1866
AN:
152308
Hom.:
Cov.:
33
AF XY:
AC XY:
906
AN XY:
74484
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Autism spectrum disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at